Anixa Biosciences Receives Korean Patent Notice of Allowance for Breast Cancer Vaccine Platform

Anixa Biosciences has received a Notice of Allowance from the Korean Ministry of Intellectual Property for a patent related to its breast cancer vaccine technology. This patent will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in South Korea. Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. The patent expands Anixa's global intellectual property coverage and reinforces its leadership in the field of cancer immunotherapy.